The Report Covers US Diabetes Devices Companies and It is Segmented by Management Devices (insulin Pumps, Insulin Syringes, Cartridges in Reusable Pens, Insulin Disposable Pens, and Jet Injectors) and Monitoring Devices (self-Monitoring Blood Glucose and Continuous Glucose Monitoring). The Report Offers the Value (in USD) for the Above Segments.

U.S. Diabetes Devices Market is size is valued at USD 44.36 Billion by 2032 and CAGR 6.5% Market by Indications by Distribution Channels.

The US diabetes devices market, a significant segment of the global market, is experiencing robust growth, driven by the rising prevalence of diabetes and an aging population. The market, valued at approximately $25.16 billion in 2025, is projected to expand at a Compound Annual Growth Rate (CAGR) of 6.27% from 2025 to 2033. This growth is fueled by several key factors: increasing adoption of continuous glucose monitoring (CGM) systems offering improved diabetes management, technological advancements leading to smaller, more user-friendly devices, and growing awareness of the benefits of proactive diabetes care. The market is segmented into monitoring and management devices. Within monitoring, self-monitoring blood glucose (SMBG) devices, including glucometers, test strips, and lancets, remain a substantial portion, although CGM is experiencing faster growth due to its real-time data capabilities and improved patient outcomes. The management device segment is dominated by insulin delivery systems like insulin pumps, syringes, pens, and jet injectors, with insulin pumps showing particularly strong growth prospects due to their convenience and efficacy in managing insulin delivery. Competitive intensity is high, with major players like Abbott, Medtronic, Dexcom, and Novo Nordisk vying for market share through continuous innovation and strategic partnerships. The North American region, particularly the US, holds a significant market share owing to high diabetes prevalence, advanced healthcare infrastructure, and strong regulatory support for innovative medical technologies. The market's growth trajectory is expected to remain positive through 2033, although certain restraints could influence the pace. These include high costs associated with some devices, particularly CGMs and insulin pumps, creating access barriers for some patients. However, increasing insurance coverage and the development of more affordable alternatives are mitigating these challenges. Furthermore, technological advancements, such as the integration of artificial intelligence and machine learning in diabetes management, are expected to further enhance the market's potential. Companies are focusing on developing integrated systems that combine CGM with insulin delivery, providing a more holistic approach to diabetes management. This trend will likely drive further growth and consolidation within the market. Future success will depend on companies' ability to innovate, offer competitive pricing strategies, and address the evolving needs of patients. Recent developments include: August 2023: The US Food and Drug Administration (FDA) has granted clearance for Roche's Accu-Chek Solo micropump system, a tubing-free "patch" pump for people with diabetes who use insulin., March 2022: Dexcom released G7 first in the U.K. and was expected to expand the launch across Europe throughout 2022. Meanwhile, the CGM system currently is under review by the Food and Drug Administration for an eventual U.S. release.. Key drivers for this market are: Increasing Number of Preterm and Low-weight Births, Advanced Technology in Fetal and Prenatal Monitoring. Potential restraints include: Stringent Regulatory Procedures. Notable trends are: Growing Diabetes and Obesity Population in the United States.

The US diabetes devices market, a significant segment of the global market, is experiencing robust growth, driven by rising diabetes prevalence, technological advancements in continuous glucose monitoring (CGM) systems, and increasing demand for convenient and effective diabetes management solutions. The market, valued at approximately $25.16 billion in 2025, is projected to exhibit a Compound Annual Growth Rate (CAGR) of 6.27% from 2025 to 2033. This growth is fueled by several key factors. Firstly, the aging population and increasing sedentary lifestyles contribute significantly to the surge in diabetes cases, creating a larger patient base requiring these devices. Secondly, the continuous innovation in CGM technology, offering real-time glucose monitoring and improved accuracy, is transforming diabetes management. These advancements are driving adoption rates and market expansion. Thirdly, the growing awareness of the importance of proactive diabetes management and self-care is influencing individual choices regarding devices and treatment strategies. While the market demonstrates substantial growth potential, certain factors could restrain its expansion. These include high device costs, particularly for advanced technologies like insulin pumps and CGM systems, which may limit accessibility for some patients. Furthermore, reimbursement policies and insurance coverage can impact market penetration, particularly in regions with limited healthcare access. The market is segmented into self-monitoring blood glucose (SMBG) devices (including glucometers, test strips, and lancets), continuous glucose monitoring (CGM) devices, and insulin delivery devices (such as insulin pumps, syringes, pens, and jet injectors). Competitive landscape analysis reveals key players such as Abbott, Dexcom, Medtronic, and Novo Nordisk, each contributing significantly to market share across various device categories. The North American region, specifically the United States, is expected to maintain a dominant market share owing to its advanced healthcare infrastructure, high diabetes prevalence, and strong regulatory support for innovative medical technologies. The future of the US diabetes devices market appears bright, with continued growth anticipated across various segments, driven by technological advancements, increasing awareness, and a growing patient population. However, addressing affordability and accessibility concerns remains crucial for ensuring market expansion and improved patient outcomes. Recent developments include: August 2023: The US Food and Drug Administration (FDA) has granted clearance for Roche's Accu-Chek Solo micropump system, a tubing-free "patch" pump for people with diabetes who use insulin., March 2022: Dexcom released G7 first in the U.K. and was expected to expand the launch across Europe throughout 2022. Meanwhile, the CGM system currently is under review by the Food and Drug Administration for an eventual U.S. release.. Notable trends are: Growing Diabetes and Obesity Population in the United States.

The United States Diabetes Care Drugs and Devices Market is Segmented by Product Type (Devices [Monitoring Devices, and More] and Drugs [Insulin Drugs, and More]), Diabetes Type (Type 1 Diabetes and Type 2 Diabetes), Age Group (Adult, Geriatric, and More), and Distribution Channel (Offline and Online). The Market and Forecasts are Provided in Terms of Value (USD).

United States Diabetes Care Devices Market is predicted to grow at a promising CAGR during the forecast period from 2020-2027

Snapshot img

Diabetes Management Devices Market Size 2024-2028

The diabetes management devices market size is forecast to increase by USD 13.98 bn at a CAGR of 7.68% between 2023 and 2028.

The market is witnessing significant growth due to the rising global burden of diabetes and the increasing focus on advanced technologies such as artificial pancreas systems. These systems utilize insulin pumps and continuous glucose monitoring sensors to automatically adjust insulin delivery based on real-time glucose levels. Additionally, the integration of artificial intelligence and data analytics in diabetes management devices is revolutionizing the industry, enabling remote patient monitoring and personalized treatment plans. Other trends include the development of insulin pens with advanced features and the adoption of spectroscopy technology for non-invasive blood glucose monitoring. However, the prohibitive cost of diabetes care devices remains a major challenge for market growth.Overall, the market is expected to experience robust growth In the coming years, driven by technological advancements and the increasing prevalence of diabetes.

What will be the Size of the Diabetes Management Devices Market during the Forecast Period?

Request Free SampleThe market encompasses a range of technologies designed to assist individuals in managing their diabetes, including insulin delivery devices, mobile health applications, and disease management tools. With the global diabetic population projected to reach over 592 million by 2035, driven by factors such as obesity rates, smoking, and high cholesterol levels, the market for diabetes care devices is experiencing significant growth. Hospitals and specialty clinics are increasingly adopting minimally invasive devices, such as diabetes lancet devices and diabetes tracker devices, to improve patient care and outcomes. Type 1 diabetes, an autoimmune disease characterized by insulin deficiency, and Type 2 diabetes, often associated with insulin resistance, both require ongoing management to prevent complications, including kidney failure, gangrene, and lower limb amputation.Insulin delivery devices, including insulin pens and blood glucose level monitoring systems, are essential tools in managing both types of diabetes. The market for diabetes management devices is expected to continue expanding as technology advances and the global population ages.

How is this Diabetes Management Devices Industry segmented and which is the largest segment?

The diabetes management devices industry research report provides comprehensive data (region-wise segment analysis), with forecasts and estimates in 'USD billion' for the period 2024-2028, as well as historical data from 2018-2022 for the following segments. ProductBlood glucose monitoring devicesInsulin delivery systemsDistribution ChannelOfflineOnlineGeographyNorth AmericaUSEuropeGermanyUKFranceAsiaChinaRest of World (ROW)

By Product Insights

The blood glucose monitoring devices segment is estimated to witness significant growth during the forecast period. Diabetes management devices play a crucial role in monitoring and managing blood glucose levels for individuals with diabetes. These devices include a range of products such as insulin delivery systems, continuous monitoring systems, and glucose monitoring devices. Insulin delivery devices, including insulin pumps and pens, facilitate precise insulin administration. Continuous monitoring systems, such as continuous glucose monitoring systems (CGMs) and Mobi insulin pumps, provide real-time glucose level data through wireless transmission and dedicated apps. Glucowear, a continuous glucose monitoring system, offers non-invasive transdermal sensors and spectroscopy technology. Hospital pharmacies, retail pharmacies, and online pharmacies stock these diabetes care devices. The increasing prevalence of diabetes among the obese, elderly population, and those with conditions like high cholesterol levels, smoking, and inactive lifestyles necessitates effective diabetes management.Disease management is essential to prevent complications like kidney failure, gangrene, lower limb amputation, heart attack, blindness, and stroke. Diabetes tracker devices, such as diabetes monitoring software and artificial pancreas systems, help healthcare providers analyze glucose patterns and create treatment plans. User-friendly interfaces, visual representations, and medication adherence features enhance the efficacy of treatment. In summary, diabetes management devices, including insulin delivery devices, continuous monitoring systems, and glucose monitoring devices, are essential tools for managing diabetes and preventing complications. These devices offer precision, flexibility, and smart features, making diabetes care more accessible and convenient for individuals with diabetes. Hospital segment, diagnostic centers, diabetes clinics, and health

The US Diabetes Devices Market size was valued at 24.62 USD Billion in 2023 and is projected to reach USD 45.51 Billion by 2031 growing at a CAGR of 6.34% from 2024 to 2031.

Key Market Drivers:

Rising Diabetes Prevalence: The escalating diabetes epidemic in the United States creates unprecedented demand for advanced diabetes management technologies. With over 37 million Americans diagnosed with diabetes and millions more at risk, the market experiences continuous growth driven by critical healthcare needs. The increasing prevalence of type 2 diabetes, particularly among younger populations, necessitates innovative device technologies that can provide comprehensive, user-friendly management solutions.

Technological Innovation in Healthcare: Rapid advancements in digital health technologies, artificial intelligence and precision medical devices drive substantial market expansion. The development of smart glucose monitoring systems, integrated insulin delivery platforms and real-time health tracking technologies creates unprecedented opportunities for comprehensive diabetes management. Cutting-edge innovations enable more personalized, precise and patient-centric approaches to diabetes care.

The US Diabetes Devices Market Size Was Worth USD 23.96 Billion in 2023 and Is Expected To Reach USD 41.88 Billion by 2032, CAGR of 6.40%.

U.S. Diabetes Devices comes with extensive industry analysis of development components, patterns, flows, and sizes. The report calculates present and past market values to forecast potential market management during the forecast period between 2025 - 2033.

The diabetes care device market size is projected to grow from USD 39.82 billion in 2025 to USD 99.81 billion by 2035, representing a CAGR of 9.62% during the forecast period till 2035

The U.S. Diabetes Drugs and Devices Market size was valued at USD 60.12 Billion in 2024 and is projected to reach USD 80.92 Billion by 2032, growing at a CAGR of 3.7% from 2025 to 2032.

Key Market Drivers:

• Increasing Prevalence of Diabetes: The diabetes drugs and devices market in the U.S. is driven by the increasing prevalence of the disease, with over 37.3 million Americans living with diabetes as of 2021. This demand for effective treatment options, including diabetes drugs and monitoring devices, is expected to continue, further boosting market growth, as predicted by the CDC.

• Technological Advancements in Diabetes Management: Technology advancements, such as continuous glucose monitoring (CGM) systems and insulin pumps, are revolutionizing diabetes management, driving market growth. These devices provide precise and convenient ways to manage blood sugar levels, improving quality of life and reducing complications. The American Diabetes Association (ADA) predicts continued growth in the diabetes devices market due to these technologies.

The Latin America Diabetes Care Devices Market report segments the industry into Monitoring Devices (Self-monitoring Blood Glucose Device, Continuous Glucose Monitoring Device), Management Devices (Insulin Pump, Insulin Syringes, Cartridges in Reusable Pens, Disposable Pens, Jet Injectors), and Geography (Brazil, Mexico, Rest of Latin America). Get five years of historical data alongside five-year market forecasts.

The North America Diabetes Care Devices Market report segments the industry into Product (Monitoring Devices, Management Devices) and Geography (United States, Canada, Rest of North America). Get five years of historical data alongside five-year market forecasts.

The US diabetes drugs and devices market, a significant segment of the global market, is projected to experience robust growth, exceeding a Compound Annual Growth Rate (CAGR) of 4% from 2025 to 2033. This expansion is fueled by several key factors. The rising prevalence of diabetes, particularly type 2 diabetes, among the aging US population is a primary driver. Increased awareness of diabetes management and the availability of advanced diagnostic tools, such as continuous glucose monitoring (CGM) systems, are further accelerating market growth. Technological advancements in insulin delivery systems, including the development of smart insulin pumps and improved insulin analogs, are also contributing to market expansion. Moreover, the growing preference for convenient and effective self-management options is driving the adoption of home-based testing and monitoring devices. The market is segmented into devices (monitoring and management) and drugs (oral anti-diabetes drugs, insulin, and others), with significant contributions from both segments. Leading companies such as Novo Nordisk, Medtronic, and Abbott are actively involved in developing and marketing innovative products, further fueling market competition and growth. Despite the positive outlook, the market faces certain challenges. High costs associated with diabetes treatment, including drugs and devices, pose a significant barrier for many patients. Insurance coverage limitations and the complexities of managing diabetes can hinder treatment adherence. Furthermore, the development of new and potentially more effective treatments necessitates continuous research and development investment. However, given the substantial prevalence of diabetes and the increasing focus on effective management strategies, the US diabetes drugs and devices market is poised for substantial long-term growth, presenting significant opportunities for both established players and emerging companies. The North American region, particularly the US, is expected to retain a significant market share due to its advanced healthcare infrastructure and higher disease prevalence. Recent developments include: June 2023: The initial allogeneic (donor) pancreatic islet cellular therapy made from deceased donor pancreatic cells, Lantidra, has been sanctioned by the U.S. Food and Drug Administration for the management of type 1 diabetes. Lantidra is specifically authorized for adults with type 1 diabetes who are incapable of achieving target glycated hemoglobin (average blood glucose levels) due to recurrent episodes of severe hypoglycemia (low blood sugar) despite intensive diabetes management and education., January 2023: Bexagliflozin (Brenzavvy, TheracosBio) has been granted approval by the US Food and Drug Administration (FDA) for the management of type 2 diabetes in adults. This oral sodium-glucose cotransporter 2 (SGLT2) inhibitor, taken once daily at a dosage of 20 mg, is recommended as a supplementary treatment alongside diet and exercise to enhance glycemic control specifically for individuals with type 2 diabetes, excluding those with type 1 diabetes.. Notable trends are: Continuous Glucose Monitoring Segment is Expected to Witness Highest Growth Rate Over the Forecast Period.

US Diabetes Devices Market reached US$ 10.25 billion in 2024 and is expected to reach US$ 18.93 billion by 2033

Latin America Diabetes Devices Market growth with a 7.9% CAGR, projected to achieve a market size of USD 32.01 Billion by 2032.

The global diabetes care devices market is expected to reach USD 64.5 billion in 2024. The sales are expected to grow even higher and will be estimated at USD 117.7 billion in 2034 due to the rising diabetes population. The diabetes care devices market is anticipated to record a CAGR of 6.2% between 2024 and 2034.

Semi-annual Industry Update

Country-wise Insights

Category-wise Insights

The Diabetes Care Devices Market in Latin America is projected to grow steadily from 2025 to 2033, with a CAGR of 5.64%. The market size is valued at XX million in 2025 and is expected to reach XX million by 2033. The growth is driven by factors such as the rising prevalence of diabetes, increasing awareness about diabetes management, technological advancements in devices, and government initiatives to improve diabetes care. Key market trends include the growing adoption of continuous glucose monitoring devices, the integration of artificial intelligence and data analytics into devices, and the increasing popularity of telehealth services for diabetes management. However, challenges such as the high cost of devices, limited access to healthcare in rural areas, and reimbursement issues may hinder market growth. The market is dominated by companies such as Abbott Diabetes Care, Medtronic, Dexcom, and Roche Diabetes Care, among others. Recent developments include: January 2023: LifeScan announced that the peer-reviewed Journal of Diabetes Science and Technology published Improved Glycemic Control Using a Bluetooth Connected Blood Glucose Meter and a Mobile Diabetes App: Real-World Evidence From Over 144,000 People With Diabetes, detailing results from a retrospective analysis of real-world data from over 144,000 people with diabetes - one of the largest combined blood glucose meter and mobile diabetes app datasets ever published., October 2022: Becton, Dickinson, and Company and Biocorp announced that they had signed an agreement to use connected technology to track adherence to self-administered drug therapies, like biologics. To support biopharmaceutical companies in their efforts to improve the adherence and outcomes of injectable drugs, the two companies will integrate Biocorp's Injay technology-a solution designed to capture and transmit injection events using Near Field Communication technology to the BD UltraSafe Plus Passive Needle Guard used with pre-fillable syringes.. Key drivers for this market are: Increasing Demand for Better Dentistry and Better Aesthetic outcomes, Increase in the Disposable Income. Potential restraints include: High Cost Associated with the Digital Dentistry. Notable trends are: The Continuous Glucose Monitoring Segment is expected to witness the highest growth rate over the forecast period.

The North America Diabetes Devices market size reached US$ 13.76 Billion in 2024 and is expected to reach US$ 28.50 Billion by 2033